DISC-0974 is a monoclonal antibody commercialized by Disc Medicine, with a leading Phase II program in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis);Myelofibrosis;Post-Polycythemia Vera Myelofibrosis (PPV-MF);Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of DISC-0974’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for DISC-0974 is expected to reach an annual total of $73 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
DISC-0974 Overview
DISC-0974 is under development for the treatment of chronic inflammation and anemia in chronic kidney disease, myelofibrosis, chronic idiopathic myelofibrosis (primary myelofibrosis), post-essential thrombocythemia myelofibrosis (post-et mf), post-polycythemia vera myelofibrosis (ppv-mf). The drug candidate acts by targeting hemojuvelin. It is administered through intravenous and subcutaneous routes.
It was also under development for the treatment of iron refractory iron deficiency anemia (IRIDA), myeloproliferative disorders and anemia of chronic disease.
Disc Medicine Overview
Disc Medicine is a clinical-stage biopharmaceutical company primarily that focuses on advancing the field of hematology through the development of innovative therapies. The company’s main activities involve the research and development of treatments for hematologic diseases, with a particular emphasis on red blood cell biology. Its pipeline products include bitopertin for the treatment of erythropoietic porphyria’s, including erythropoietic protoporphyria, X-linked protoporphyria and Diamond-Blackfan Anemia:, DISC-0974 for the treatment of anemia of myelofibrosis and and anemia of chronic kidney disease. Disc Medicine is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$91.1 million in FY2023, compared to an operating loss of US$47.5 million in FY2022. The net loss of the company was US$76.4 million in FY2023, compared to a net loss of US$46.8 million in FY2022.
For a complete picture of DISC-0974’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
